Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

HALCO has expanded its product portfolio to include, Elastics, Adhesives, and new forms of Hook and Loop Fastening Systems to meet the needs of PPE DLA procurements


Halco

Halco USA Logo

We remain fully committed to our traditional products and industry focus.

HALCO USA, a leading supplier of Hook and Loop Fastening systems for a variety of applications in medical, industrial and transportation segments has mobilized to address the growing demand for Personal Protective Equipment (PPE). As the COVID-19 crisis transitions to a post-pandemic recovery, Halco is assisting manufacturers throughout the USA and Canada with components for producing the following product categories:


  • Protective Suits
  • Isolation Gowns
  • Respirators
  • 3 Ply Masks
  • Sneeze Guards
  • Face Shields
  • Temporary Shelters
  • Curtains

From the early days of the crisis, HALCO has been working with business partners in medical, industrial, exhibit/print segments to rapidly design and deliver PPE solutions to frontline workers and essential businesses. HALCO has been able to respond quickly and assist customers in meeting this new demand with:

  • Berry Compliant Seam Tape for Gown Manufacturing.
  • Domestic Reclosable Hook and Loop Fasteners for Gown Manufacturing.
  • Rotary die cutting for applications requiring specific shapes and adhesives.

The company brings extensive application experience in bringing new products to market including product suitability, life of product, adhesives, and custom packaging.

“Our company is both innovative and adaptive,” commented Guy Fussell, General Manager of HALCO USA. “We are using that spirit of innovation, in cooperation with many of our customers and manufacturing partners, to solve problems posed by the crisis and the “new normal” that lies ahead.”

Halco works with each partner to design the ideal solution, source the materials, provide precision converting and fabricating services, and manage inventory levels to ensure a steady supply.

“We remain fully committed to our traditional products and industry focus,” noted Guy Fussell. “At the same time, our COVID-19 solutions will meet a new demand for PPE while helping partners to restore revenue sources impacted by the crisis. We are agile enough to cover all the bases.”

To learn more about HALCO’s COVID-19 response, or to explore a potential PPE partnership, visit: http://www.halcousa.com

ABOUT HALCO USA

HALCO provides state-of-the-art fastening solutions based on hook and loop technology, industrial adhesives, and specialty fastening products. We use advanced technology and ISO 9001 certified methodologies to deliver superior converting services. Our personalized service brings together products, packaging, pricing, engineering, testing, and inventory programs into a total solution. HALCO products can be found in global brands like Tesla, Boeing, and Caterpillar, and we supply industrial and sewing contractors across the country with fastening systems that deliver unmatched value. For more information visit: http://www.halcousa.com

Share article on social media or email:

EvidenceCare Names Bartholomew as New Chief Executive Officer


Bo Bartholomew CEO

EvidenceCare, a leading provider of advanced Clinical Decision Support (CDS) technology, announced today that Bo Bartholomew has joined the company as chief executive officer.

Bo Bartholomew is a seasoned c-suite executive, co-founder, former president and CEO of PharmMD, now AdhereHealth. He served as chief revenue officer at Shearwater Health and is a board member at several health tech ventures. A serial entrepreneur, Bo’s track record of driving growth in health tech companies is timely given the recent integration of EvidenceCare’s platform into the interoperable “app marketplaces” of major electronic medical records (EMRs).

“I am impressed by the clinical expertise and ingenuity shown by the EvidenceCare team. Because of the pandemic, every hospital in the country is looking to marry their clinical pathways with the need for operational efficiency and financial return. EvidenceCare improves clinical decisions within the physician’s care process,” said Bartholomew. “Reducing clinical variation and improving documentation is a powerful tool every health system needs right now.”

EvidenceCare’s clinical pathway engine is fully integrated into a physician’s EMR workflow, solving a fundamental issue with content-based CDS for healthcare providers. The platform utilizes existing patient data in the medical record to deliver safe, compliant care that leads to better patient outcomes, while also allowing physicians more time to care for their patients.

“From inception to where we are today, I’m proud of the foundation our team has built and we welcome Bo’s leadership and expertise to support taking EvidenceCare to the next level,” said Brian Fengler, MD, co-founder and chief medical officer at EvidenceCare. “In my new role as chief medical officer, I will be focusing on what I’m most passionate about, building clinically-reliable solutions that empower my fellow colleagues to deliver the best care to their patients.”

“Bo is a great fit and he is joining the team at the perfect time,” said Jim Jamieson, co-founder and chief revenue officer of EvidenceCare. “The market demand is greater than ever. We have seen the ROI EvidenceCare’s platform can deliver as we create a clinically driven revenue cycle approach. Our entire team is excited about the future growth potential under Bo’s leadership.”

About EvidenceCare

EvidenceCare is the leading clinical decision support solution that drives real ROI. Founded in response to the experience of frontline physicians, the platform is integrated into a clinician’s EMR workflow, delivering customized, interactive, curated guidance directly into the care process. With EvidenceCare, hospitals, emergency departments and urgent care centers enable clinicians to deliver evidence-based care with measurable outcomes. Through EvidenceCare’s advanced technology, clinical variation is reduced, and the appropriate criteria are documented during utilization and admission decisions. With increased government-mandated compliance measures and quality program demands, health systems can now ensure that quality and safety improve, liability is reduced, and operational efficiency is increased while capturing additional revenue. To learn more, visit http://www.evidence.care or follow us on Twitter @evidencecare or on LinkedIn.

Share article on social media or email:



Bay Area Aesthetics Practice Gets a (Nonsurgical) Facelift


For more than a decade, Dr. David C. Mabrie, a facial plastic surgeon, has dedicated his practice to nonsurgical facial aesthetics. Mabrie has made a name for himself as a pioneer and thought leader in the use of injectable fillers and neuromodulators. To better serve his patients, he has expanded his solo practice by developing a team of carefully selected medical professionals, and rigorously training them in the safest, most effective facial contouring and rejuvenation techniques.

“I have always prioritized education,” Mabrie said, “both for myself and my patients. Sharing what I’ve learned and training a top-caliber clinical team to support our patients seemed like the next logical step for my practice.”

Dr. Mabrie trained at some of the country’s best medical and surgical centers, including UCSF, Johns Hopkins, and Stanford. He also trains other doctors, nurses, and medical professionals in the best safety and aesthetic practices for use with dermal fillers. With a growing number of patients seeking his services for procedures such as nonsurgical rhinoplasty, cheek and chin contouring, and “liquid facelift,” Dr. Mabrie seized the opportunity to further his commitment to education through the creation of Mabrie Facial Institute.

Each of his associate injectors and clinical support team members is hand-selected and trained by Dr. Mabrie. As a group, they share a dedication to superior care and results, and continuing to push the limits of what is possible through nonsurgical aesthetics.

The first associate injector Dr. Mabrie trained for his clinical team was Kimberly Rolley, PA-C. Kimberly has a master’s degree and a background in neurology, urology, and pediatrics. She spent more than 2,600 hours training with Dr. Mabrie as part of her onboarding as an associate injector. She said she enjoys being part of a team that takes such a meticulous approach.

“Mabrie Facial Institute is so much more than a medical spa or an aesthetics clinic where patients go for injections,” said Rolley. “We build relationships with our patients that start with in-depth conversations about how they want to look and feel. We take the time to thoroughly educate them about our process, products, and safety protocols.”

The patient relationships are long-lasting, in part because the results are, according to Rolley. “We have a unique treatment process—called Illumination 360° that involves long-term planning, careful documentation, and staging of procedures so that we can build and layer with fillers. This creates superior results that hold up, especially when you factor in the touch-up appointments that are a big part of our process.”

For most patients, this process takes the form of a procedure package—either rejuvenation, for patients showing signs of facial fatigue or aging, or contouring, for individuals who want to sculpt and refine their features. According to Dr. Mabrie, the packages allow them to do what’s best for each patient, rather than simply make injections in requested areas.

“Many people come into our office thinking they simply need filler injected into a specific area, such as the nasolabial folds or under-eye area. What we’ve found through years of experience and thousands of treatments is that often we need to treat adjacent areas to produce the improvements our patients really want. This is why we developed procedure packages to comprehensively address our patients’ most common concerns.”

Educating patients about the benefits of the comprehensive Illumination 360° approach has been a major focus of the newly branded Mabrie Facial Institute. Dr. Mabrie, Kimberly, and the other associates have prioritized this education campaign through social media posts, informative videos, blog posts, and a revamp of the practice website.

“We’re really excited about the growth of the practice, but we’re even more excited about the remarkable results we’re able to achieve for our patients,” said Dr. Mabrie. “We made a conscious choice to do things differently—to take a surgical approach to fillers—and it’s gratifying to see people embracing that and enjoying the rewards.”

Mabrie Facial Institute (http://www.yourfaceinourhands.com) is a facial rejuvenation and contouring destination in the San Francisco Bay Area of California, founded in 2002 by Dr. David C. Mabrie. His team of highly trained injectors specializes in nonsurgical rejuvenation and contouring of the nose, face and neck. After graduating with honors from University of California San Francisco School of Medicine, Dr. Mabrie completed a residency in head and neck surgery at the prestigious Johns Hopkins Hospital in Baltimore. He went on to complete a fellowship in facial plastic and reconstructive surgery at Stanford University.

Share article on social media or email:

SeKON Enterprise, Inc. Wins a $6.7M COVID -19 Digital Support Web Services Contract at CDC


“SeKON and our partners, Northrop Grumman and AditTech, are looking forward to supporting CDC, on this critically important work to facilitate the dissemination of information regarding the COVID-19 pandemic,” said SeKON’s President and CEO, Dr. Angela Wilson.

SeKON announced today that it has been awarded a task order to secure web services for CDC’s COVID-19 website including web development, programming support for advanced web products, usability support and metrics analysis for this critical website. The work is under CDC’s Office of the Associate Director for Communication (OADC) Digital Media Branch (DMB). This task order was awarded under NITAAC’s CIO-SP3 contract vehicle.

OADC DMB is responsible for providing systems, applications, services, tools, guidance, policies, and procedures that position CDC as a leader in digital health communications. To support OADC’s public health objectives, SeKON will provide continuous development, improvement, innovation, and support of the COVID-19 website, including website production, day-to-day usability, testing, programming, and software architecture support. “SeKON and our partners, Northrop Grumman and AditTech, are looking forward to supporting CDC, on this critically important work to facilitate the dissemination of information regarding the COVID-19 pandemic,” said SeKON’s President and CEO, Dr. Angela Wilson.

About SeKON:

SeKON has been supporting CDC’s Division of HIV/AIDS Prevention (DHAP) for over four years, focusing on CDC’s HIV websites with outstanding results in service delivery, management, quality, and innovation. SeKON’s more than 20 years of experience in the federal health and public health sectors, brings rich domain expertise and a unique understanding of the user experience, the business demands of stakeholders, and the use of technology in the advancement of health, public health and life sciences. For more information, follow us on LinkedIn – https://www.linkedin.com/company/sekon.

Share article on social media or email:

SchoolStatus Announces Availability of Contact Tracing Capabilities


News Image

We’re proud to pair these new contact tracing capabilities with our two-way communication platform to ensure that the families are informed and students are safe and comfortable in their learning environment,” said Russ Davis, CEO of SchoolStatus.

As schools evaluate safely reopening this fall, SchoolStatus, the district-wide communication and student data platform, announces the availability of contact tracing reports and tracking. The new compliance feature adheres to the Centers for Disease Control (CDC) guidelines to help schools efficiently communicate if a student or faculty member tests positive for COVID-19 and monitor quarantine start and end dates.

“We understand that schools will need to frequently communicate with the school community this Fall. This communication needs to be more than a general mass message because guardians will have questions and need quick answers,” said Russ Davis, CEO of SchoolStatus. “We’re proud to pair these new contact tracing capabilities with our two-way communication platform to ensure that the families are informed and students are safe and comfortable in their learning environment.”

In such a circumstance, school or district leaders can use SchoolStatus’ contact tracing report feature to generate a list that includes the infected student’s current schedule, names of teachers for each course in the section and names and ID numbers of all students who are also in the same sections. Adhering to CDC guidance, administrators can then communicate to those on the contact tracing report to take precautionary measures.

With SchoolStatus, administrators can:

  • Obtain critical data: Administrators must find and isolate the school community who may have come in contact with someone infected or symptomatic with COVID-19. SchoolStatus pulls this data and identifies which students share the same classes or schedules. SchoolStatus also monitors individuals’ quarantine start and end dates to determine when they could potentially return to school.
  • Communicate efficiently: Using SchoolStatus’ communication tools, administrators can quickly send group communications specifically to those in the contact tracing report to alert them of potential exposure, inform best practices and outline next steps in an effort to contain a potential outbreak.
  • Maintain privacy: The Americans with Disabilities Act and the Family Education Rights and Privacy Acts require confidentiality of students or staff members. Communications deployed through SchoolStatus are received as a one to one communication which enables families to reply directly and privately with questions and concerns.
  • Demonstrate compliance: Communications are logged and recorded within SchoolStatus to demonstrate appropriate school and CDC compliance.

“Having a single place to generate contract tracing reports and track student’s COVID-19 quarantine data is critical for our district. During these tough times, every minute of every day counts,” said Dr. Michelle Bivens, Superintendent, Pontotoc City School District.

SchoolStatus’ contact tracing feature pairs its data and communication tools to support districts in meeting CDC compliance and ensuring safe and healthy learning environments for students. To support districts’ communication efforts, SchoolStatus has prepared a Contact Tracing Toolkit which includes communication resources like contact tracing announcement templates, positive case checklist, CDC resources and more.

For more information about SchoolStatus’ new contact tracing feature, please visit https://www.schoolstatus.com/covid19.

About SchoolStatus

SchoolStatus is the district-wide communication tool that integrates key student data in order to increase communication among educators, district administrators and student families. The company’s solution aggregates individual student data, such as state assessments, attendance and grades in an easy-to-visualize format and offers the option to communicate with student families via call, text or email. Through SchoolStatus, millions of communications have occurred on the classroom, campus and district level. For more information about SchoolStatus, visit http://www.schoolstatus.com.

Share article on social media or email:

HunterPark Productions and NAMI-NYC Premiere Mental Health PSA, INSIDE & OUTWARDS, Featuring Musical Score by Sufjan Stevens with Narration by Sarah Jessica Parker


HunterPark Productions today announced the world premiere of the PSA Inside & Outwards in partnership with the National Alliance on Mental Illness of New York City (NAMI-NYC). The film explores mental health and the feeling of isolation created by Covid-19, while celebrating inner strengths that emerged during the pandemic. The film was produced by HunterPark partners Bethanie Schwartz and Lauren Tuttman in collaboration with Marissa Velez.

Narrated by acclaimed actress and producer Sarah Jessica Parker, Inside & Outwards is directed by filmmaker Ezra Hurwitz. The score, by Oscar and Grammy-nominated artist Sufjan Stevens, features music from his recently released album Aporia, and powerfully marries the narration with choreography by Justin Peck (Tony winner; New York City Ballet resident choreographer). Hurwitz created the project in collaboration with creative director Ezequial Consoli and writer Kyle Harrison. The intertwining vignettes are seamlessly woven together by Editor Will Town from Modern Post, marrying the individual worlds of each character into a unified experience.

“This film came together in the true spirit of remote collaboration, underscoring the film’s theme of connectedness amidst isolation – being ‘alone together,’” said producer Bethanie Schwartz. “Our incredible roster of talent generously lent their time and passion, with a common goal of uplifting viewers while inspiring awareness and support to all those struggling with mental health as a result of the pandemic.”

Inside & Outwards features performances by Sara Mearns (principal dancer, New York City Ballet), Dharon Jones (Broadway revival, West Side Story), Emma Portner (acclaimed choreographer/activist), Ehlie Luna (artist/musician), Robert Fairchild (Tony-nominated actor/dancer), Gabriel Kane Day-Lewis (actor, model, musician), Brianna Lance (visual artist), Jasmine Rice (artist/performer), Carlos Gonzalez (Steven Spielberg’s remake of West Side Story) and Maira Barriga (artist/model). The cast also shares their own personal struggles with mental health in an intimate, behind-the-scenes featurette.

Released on World Suicide Prevention Day, the PSA inspires viewers to embrace their vulnerabilities while celebrating their inner strength, taking comfort and pride in our collective resilience during the pandemic. A call to action caps the film, directing viewers, and anyone struggling with mental health issues, to local NAMI support resources. Additionally, the Inside & Outwards PSA teasers will be shown on select broadcast stations around the country.

Visit http://www.naminycmetro.org/insideoutwards to learn more about Inside & Outwards. Follow on social media using #InsideandOutwards and #MentalHealthForAll.

About HunterPark Productions

HunterPark is a proudly female-owned and operated creative production agency, WOSB and WBENC certified. The company produces a diverse spectrum of work from compelling and powerful original content to nimble and high-end campaigns. The company ethos stands by maintaining the quality of large corporations with the intimate hands-on service of a boutique shop. For more information, please visit http://www.hunterpark.tv.

About the National Alliance on Mental Illness of New York City (NAMI-NYC)

For nearly 40 years, the National Alliance on Mental Illness of NYC (Matt Kudish, executive director) has offered life-changing support, education, and advocacy programs to families and individuals affected by mental illness. NAMI-NYC’s services are free of charge and accessible for anyone who needs them, regardless of age, race, or background. For more information about NAMI-NYC and its programs and services, please visit http://www.naminyc.org/coronavirus.

Share article on social media or email:

Award-winning All-In-One Black Seed Oil Blend Goes Above & Beyond Mere Skincare By Providing Pain Relief & Healing Dermatitis


Before and after images of PRĀZ Naturals customer, Peter, treated and healed dermatitis using All In One Oil.

Studies have shown that half of Americans are unaware that the products they use every day contain petroleum-based ingredients or petrochemicals.

PRĀZ Naturals​, a skincare company that focuses on fresh all-natural ingredients and clean, easy-to-use products, today announced that fans of their All In One Oil have reported added benefits beyond delivering urgent moisture, smoothing skin, restoring thinning hair and fighting the signs of aging. Prāz’s commitment to all-natural skincare has culminated in their All In One Oil – a lightweight moisturizer for use “all over” that is the ultimate skincare genie in a bottle – granting healing for aching joints, inflamed skin and ultra-moisture for skin, hair, and nails.

The popular 10-step Korean skincare craze, compounded with a booming online skincare industry, has resulted in more people accumulating multiple products and adopting a maximalist daily regimen. Unfortunately, an overload of ingredients – especially harsh chemical ingredients – can lead to skin problems and irritation. A recent study conducted by OnePoll for Groupon has found that the average woman spends $3756 per year on her appearance due to sheer volume of product. PRĀZ Naturals’ All In One Oil is a one step skincare option that works not just to repair the skin barrier from damage and irritation from too many products, but its antioxidants also have the benefit of aiding in dermatitis and minor burns, treating thinning hair, and delivering Omega 3,6, & 9 to fight aging all in one simple step.

The active ingredient of black seed oil has been used for centuries in parts of Asia and the Middle East. Black seeds were reportedly found in King Tut’s tomb and the ancients often relied on its anti-microbial and anti-inflammatory properties. The All In One Oil from PRĀZ uses black seed oil as well as plant-based antioxidants combined with vitamins C and E to deliver UV protection while minimizing red skin, and reducing hyper-pigmentation. However, it’s the oil’s healing properties have come as a boon to those who suffer from skin ailments and often face the issue of being unable to easily find eco friendly options that are free of chemicals to treat those ailments.

“Studies have shown that half of Americans are unaware that the products they use every day contain petroleum-based ingredients or petrochemicals.” Says Sasha Nialla, Founder of PRĀZ Naturals. “That’s 165 billion people that are unknowingly welcoming toxins into their homes – and it wasn’t too long ago that I was one of them. All it takes is shopping more consciously and making the decision to choose eco-friendly products that can be the start in treating skin and other health ailments.”

Another active ingredient, Eucalyptus oil, acts as a natural antiseptic that relaxes muscular aches and aids in sore joints. Other ingredients include Phytic and Ferulic acid as well as Rosehip seed oil – integral for firming and reducing the appearance of fine lines, brown spots and scars. The All In One Oil also is made with pure rice bran oil, organic sunflower, avocado, black cumin, Jojoba, lemon and purple coneflower oils. The resulting blend has a fan base with users using it to treat sunburns, flaky scalp, joint pain and even as shaving oil. Its versatility makes it an ideal choice in a time of overwhelming choice for products that are ethical and actually deliver real results.

“For two years, I battled with dermatitis. Under the care of a dermatologist, using various creams and lotions, nothing worked.” says Peter, a PRĀZ customer. “I was introduced to PRĀZ’s All In One Oil and thought it couldn’t hurt to give it a try. Within two weeks of using the All In One, I have experienced better results – no itching, no flakes, no burning – than I have in the past two years. In the time I have been using PRĀZ, I could not be happier with the results.”

The All In One has received the “Best Multi-Tasking Eco product” Award from the 2020 Beauty Shortlist Awards. As with all Prāz Naturals products, the oil is formulated with 100% USDA certified organic ingredients and is G.M.O. Free, synthetic-free, paraben-free and cruelty-free. With its one small bottle users of the All In One Oil can save time, money and deliver less stress on their skin resulting in a minimalist routine for maximum gain.

About PRĀZ Naturals

PRĀZ Naturals offers a skincare routine worth celebrating and only gets better as they continue to explore and discover powerful plant-based ingredients. With a foundation built on appreciation, wellness and a commitment to the environment – PRĀZ ensures responsible business practices and manufactures every product by hand. The ultimate goal is to source and share their products in a way that honors humans, animals, and the planet.

Share article on social media or email:

Gilsbar Coach Offering Coach-to-Member Virtual Call Capabilities


“This new feature gives our clinicians the ability to communicate face-to-face with members via Zoom at their convenience. It’s a great new addition that allows us to provide an even higher level of service to improve the health of our members.”

Gilsbar Coach is an engagement app designed for quick and secure clinical messaging between Gilsbar personal health coaches and nurses and Gilsbar members. Gilsbar health coaches and nurses communicate on topics specific to members’ individual health objectives with the goal of creating actionable steps to improve overall health.

Gilsbar is focused on finding better ways to engage with our members and creating happier constituents and healthier bottom lines. We’re excited to share Gilsbar Coach will offer secure, virtual face-to-face clinician services, starting in 2021.

Paul Johnson, Senior Director of Population Health Management, shared “Due to COVID-19, many people are spending more time inside their homes and less time interacting with their health care providers. This new feature gives our clinicians the ability to communicate face-to-face with members via Zoom at their convenience. It’s a great new addition that allows us to provide an even higher level of service to improve the health of our members.”

Gilsbar Coach and our Population Health Management program provides your organization with a combination of proactive educational and personalized solutions. Both are key features—and they work in tandem to create a fully-integrated approach. Our strategic outreach plan addresses the entire healthcare continuum, improving all risk categories: acute, chronic, diagnosed, and healthy/at risk. The personal outcomes—and related cost savings—speak for themselves. To learn more about Gilsbar Coach and how it can be integrated into your current benefit plan, reach out to Gilsbar today.

About Gilsbar, LLC

Established in 1959, Gilsbar, LLC® is one of the largest privately-held insurance services organizations in the United States. Recognized as a catalyst for creating healthy businesses, Gilsbar, LLC® offers self-funded and fully-insured benefit plan management services, along with Wellness, Advocacy, and overall Population Health Management. Gilsbar, LLC®’s integrated delivery model improves the health and well-being of its members, resulting in significant health plan savings for its clients.

Gilsbar, LLC® has been honored by Inc. magazine for its sustained growth, Modern Healthcare and Business Insurance magazines as a Best Place to Work, and WELCOA and the American Heart Association for its proven wellness methodology.

For more information, visit http://www.Gilsbar.com.

Share article on social media or email:

International Clinical Guidelines for the Rare Disease HHT Updated For The First Time Since 2006


Christopher McMahon Memorial International HHT Clinical Guidelines

“These Guidelines will ensure effective and comprehensive treatment of HHT for patients worldwide,” stated Marianne Clancy, Exec. Director of Cure HHT. “Our efforts to successfully pair attendees, which included for the first time the powerful voice of HHT patients who battle this disease daily.”

In a critical effort to foster consistent, state-of-the-art care for people suffering from the hereditary disease HHT, Cure HHT hosted the Christopher McMahon Memorial International HHT Guidelines Conference in November, 2019, in Toronto, Canada. Completely underwritten by the generous support of the McMahon family, who have been deeply affected by the disease, the conference brought together 65 clinical physicians and patients from 14 countries and resulted in comprehensive new International Clinical Guidelines, just published in the Annals of Internal Medicine. The complete Guidelines are now available: visit https://curehht.org/ Cure HHT is the largest HHT advocacy organization and the epicenter of the national and global effort to advocate for HHT patients and families, raise awareness, sponsor critical research, advance treatments and find a cure.

HHT (Hereditary Hemorrhagic Telangiectasia), also known as Osler-Weber-Rendu Syndrome, is a genetic disease that affects families for generations. As common as ALS (Lou Gehrig’s Disease), it is the second most common bleeding disorder, affecting 1 in 5,000 people (an estimated 1.4 million worldwide). However, the disease is not well known and only 10% of those with HHT know that they have it. It causes malformed blood vessels in multiple organs of the body and typically begins with nosebleeds during childhood. HHT can result in stroke, brain abscess, anemia and heart failure, but proper diagnosis and treatment can prevent most of these complications.

Cure HHT has significantly advanced the awareness, treatment and research of the disease, especially over the past 15 years. Cure HHT is the only disease advocacy group supporting HHT patients in the United States, and the only one working across international boundaries. It sponsors and produces the biennial International Scientific Research Conference, most recently held in Puerto Rico in 2019, which brings together patients, scientists and physicians and provides an opportunity for cross-fertilization of ideas and research. Cure HHT has helped leverage more than $34 million in research grants since 2004, and has created and monitors 26 HHT Centers of Excellence (CoE) at hospitals and universities in the United States and Canada.

The HHT International Clinical Guidelines are used in all HHT Centers of Excellence for all clinical decisions related to HHT screening, management and patient care. In contrast to previous approaches in medicine, which were often based on tradition or authority, modern medical guidelines are based on an examination of current evidence within the paradigm of evidence-based medicine. They usually include summarized consensus statements on best practice in healthcare. A healthcare provider is obliged to know the medical guidelines of his or her profession and has to decide whether to follow a guideline’s recommendations for treatment. These guidelines can also be used by other medical professionals throughout the world, not affiliated with a CoE, who are seeing HHT patients. The Guidelines also dictate insurance reimbursement coverage for HHT patient screenings, treatments and surgeries.

Scientific and clinical advances have dramatically impacted the trajectory of HHT since the last Guidelines created in 2006, making it even more imperative that new and expanded Clinical Guidelines be developed to include new research and treatments, and to include significant changes and areas that were previously not addressed including pediatrics, anemia, pregnancy, gastrointestinal bleeding, liver AVMs and cardiac involvement. Furthermore the process of bringing together clinical and medical experts to seek consensus based on the wealth of available evidence creates a fertile environment for collaboration and new approaches.

“We couldn’t be prouder that our support of the Toronto conference has resulted in such a game-changing outcome,” comments Chandra McMahon, former Board Chair of Cure HHT. “The new Guidelines will have a profound impact on HHT screening, diagnosis and treatment. They will positively affect every person with HHT, a wonderful tribute to my brother-in-law Christopher and everyone in our family who has been affected by this disease.”

“These new Guidelines are an important turning point in the treatment of HHT,” adds Dr. Marie E. Faughnan, Director of the Toronto HHT CoE and Co-Chair of the Guidelines Conference. “The Guidelines provide a new plateau of shared knowledge, allowing doctors everywhere to further advance our service to our patients and our understanding of this complex disease.”

“These Guidelines will ensure effective and comprehensive treatment of HHT for patients worldwide,” stated Marianne Clancy, Executive Director of Cure HHT. “Our efforts to successfully pair attendees, which included for the first time the powerful voice of HHT patients who battle this disease daily with the medical experts, was the key to the successful completion of our new clear and cohesive Guidelines. ”

Most recently, Cure HHT was honored to receive a two-year capacity-building grant from the Chan Zuckerberg Initiative’s “Rare As One” Project to develop a patient-led Research Network which will accelerate its mission to find new treatments and a cure for the disease. A key driver of its success as the only international patient-led advocacy group supporting HHT patients has been its constant focus on collaboration between physicians, scientists and patients.

The HHT International Clinical Guidelines are indicative of how that kind of collaboration can create a new level of shared knowledge and best practices, propelling forward new understanding and state-of-the-art patient care for a rare disease.

For information, visit http://www.curehht.org call 410-357-9932 or connect on Twitter or Facebook.

Editors Note:     

  • Additional background on HHT and Cure HHT available on request.
  • Interviews are available with Marianne Clancy and with experts at the 26 HHT North American Centers of Excellence including Augusta University; Cincinnati Children’s Hospital Medical Center; Cleveland Clinic; Froedtert & Medical College of Wisconsin in Milwaukee; Johns Hopkins in Baltimore, MD; Massachusetts General Hospital; Mayo Clinic – Rochester Minnesota; New York-Presbyterian Hospital / Columbia University Irving Medical Center; Oregon Health and Science University; Stanford Health Care; University of Arkansas Medical Sciences; University of California San Francisco; University of California, Los Angeles; University of Chicago Medical Center; University of Colorado Hospital; University of North Carolina at Chapel Hill; University of Pennsylvania; University of Texas Southwestern; University of Utah Medical Center; UPMC and The University of Pittsburgh; Washington University School of Medicine in St. Louis, MO; Yale University School of Medicine; and in Canada in Edmonton, Montreal, Toronto, and Winnipeg.

Share article on social media or email:

How “Tumor on a Chip” Can Transform Drug Development


Draper bio engineer Vienna Mott holds a new device for testing cancer treatments that can reduce testing from weeks to days. Credit: Draper.

“Here we demonstrate for the first time that a dynamic tumor microenvironment can distinguish differences between two different ICI therapies,” said researchers at Draper and Charles River Laboratories.

Animal models have long been the standard in drug development and cancer research. Now, a team of engineers has developed a test bed that creates just the right conditions for testing on tumor tissue in real-time. The impact could be significant for cancer researchers and drug developers interested in translating scientific findings into practical clinical applications, such as cancer therapies, sooner.

The team, led by Draper, tested the device, called EVIDENT, to see if they could suppress tumor growth using a type of immunotherapy called immune checkpoint inhibitor (ICI) equally well in a living mouse as on a mouse tumor tissue residing in the EVIDENT device.

ICIs have shown remarkable success against melanoma, non-small-cell lung cancer and Hodgkin’s lymphoma. The new approach is described in the peer-reviewed archival International Journal of Molecular Sciences, written by Jeff Borenstein, Vienna Mott and Cassie Bryan of Draper, John Ho and Julia Schueler of Charles River Laboratories and Daniel Doty and Nathan Moore, both formerly of Draper.

“We found excellent correlations between in vivo syngeneic mouse model and in vitro tumor biopsy responses to checkpoint inhibitors,” the authors said. “Here we demonstrate for the first time that a dynamic tumor microenvironment can distinguish differences between two different ICI therapies, anti-CTLA4 and anti-PD-1, against three different syngeneic mouse lines, MC38, CT26 and B16F10.”

Models recapitulating the tumor microenvironment have been in development for more than a decade. But they are typically static systems that do not capture the dynamics of lymphocyte migration and drug transport, and they are limited to a very short experimental duration due to the rapid decline in tissue viability, typically within 24 to 72 hours.

“An urgent need exists for engineered platforms capable of supporting viable tumor fragments for periods of a week or longer,” Borenstein said. “Our tests show that EVIDENT can accommodate dynamic interactions between lymphocytes and tumors and is compatible with real-time imaging and quantification of tumor killing and lymphocyte infiltration in response to ICI treatments.”

While it’s likely that animals will continue to play a key role in drug development, researchers are now trialing new treatments and, with platforms like EVIDENT, can opt to augment trials with tissue, including potentially human tumor tissue, that can be tested in real time.

“The main advantage to EVIDENT is speed and throughput, since we obtain an answer in seven days as compared to six weeks in a mouse, and we can run 12 experiments in EVIDENT versus one in a mouse,” Mott explained. “The other advantage is that we can observe mechanisms—minute-by-minute, if required—in an in vitro system that cannot be observed in a living animal.”

Julia Schueler, Research Director at Charles River Laboratories, said, “The EVIDENT platform is a valuable asset to oncology drug development because it has the potential to enable faster investigational new drug (IND) filings, as well as supporting animal welfare as an important contribution to the 3Rs principle (replace, reduce and refine).”

EVIDENT stands for Ex Vivo Immuno-oncology Dynamic ENvironment of Tumor biopsies. The system features organ-on-a-chip technology, flow-control using a single pump, low-absorption materials and the ability to connect to Draper’s customizable image analytic algorithms to provide automated and quantitative assessment of experimental results. EVIDENT enables cancer researchers to evaluate how ICIs and other drugs arm the immune system to kill tumors in a high-throughput, scalable configuration.

Charles River provided the materials used in the research.

Share article on social media or email: